1. Introduction {#sec1-cancers-11-00809}
===============

Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors that originate from neural crest-derived chromaffin cells and develop either in the adrenal medulla or in extra-adrenal sympathetic and parasympathetic ganglia. PPGLs show the highest heritability of all cancers with almost 40% of patients carrying pathogenic germline mutations in one of the known PPGL susceptibility genes. \[[@B1-cancers-11-00809],[@B2-cancers-11-00809],[@B3-cancers-11-00809],[@B4-cancers-11-00809],[@B5-cancers-11-00809]\] For this reason, current guidelines recommend that germline genetic testing should be considered in all patients with PPGLs, regardless of family history and age at diagnosis \[[@B6-cancers-11-00809]\]. Identification of a predisposing germline variant enables predictive testing in PPGL families, clinical surveillance of healthy mutation carriers and risk stratification for malignant disease and for development of synchronous and metachronous tumors.

The majority of hereditary PPGLs are caused by mutations affecting *NF1*, *RET, VHL, SDHA, SDHB, SDHC* and *SDHD*. Rare underlying germline mutations have been described in *FH, MAX, SDHAF2* and *TMEM127.* \[[@B2-cancers-11-00809],[@B7-cancers-11-00809],[@B8-cancers-11-00809],[@B9-cancers-11-00809],[@B10-cancers-11-00809],[@B11-cancers-11-00809]\]. Genetic testing of these genes in PPGL patients in routine diagnostics has previously been conducted according to a step-wise diagnostic algorithm \[[@B2-cancers-11-00809]\]. With next generation sequencing techniques becoming cheaper and more commonly available, multi-gene panel sequencing is increasingly replacing targeted approaches. Recently, several additional susceptibility and candidate genes accounting for a small proportion of cases have been identified. These are, however, not yet commonly included in routine diagnostic analyses of affected patients. These include germline mutations in genes encoding components of metabolic pathways, e.g. *MDH2*, *GOT2* and *DLST* \[[@B12-cancers-11-00809],[@B13-cancers-11-00809],[@B14-cancers-11-00809]\] and in hypoxia pathway related genes *EGLN2* (*PHD1*), *EGLN1* (*PHD2*), and *EPAS1 (HIF2α)* \[[@B15-cancers-11-00809],[@B16-cancers-11-00809]\]. Mutations in the latter usually occur somatically but can be associated with a syndromic presentation when they occur in mosaic forms \[[@B17-cancers-11-00809]\]. Similarly, a case with a postzygotic mosaic mutation in *H3F3A* presenting with PPGLs and a giant cell tumor of the bone has recently been described \[[@B18-cancers-11-00809]\].

Recent efforts in genomic analyses of PPGLs revealed that about 30% of tumors carry somatic mutations in known susceptibility and driver genes \[[@B19-cancers-11-00809]\]. Furthermore, somatic mutations in known cancer associated genes have been identified as driver-alterations in a subset of PPGLs due to recent efforts in genome sequencing projects, such as somatic activating hot-spot cases, and somatic hot-spot mutations in *IDH1* or *IDH2,* recognized as drivers of tumorigenesis in PPGL, were identified \[[@B20-cancers-11-00809],[@B21-cancers-11-00809]\]. In addition, somatic alterations in other cancer-associated genes, such as *SETD2, EZH2, FGFR1, BRAF, MET,* and *TP53,* have been reported \[[@B18-cancers-11-00809],[@B19-cancers-11-00809],[@B22-cancers-11-00809]\].

Supporting analyses of tumor tissue by immunohistochemistry and metabolite measurements provide further information, aiding in identification and interpretation of genetic variants \[[@B21-cancers-11-00809]\]. We previously demonstrated that quantification of Krebs cycle metabolites in tumor tissue can classify PPGLs and identify tumors with underlying alteration in *SDH-*genes (*SDHx*), *FH*, and *IDH-*genes *(IDHx)* and can furthermore aid in classification of variants of unknown significance in *SDHx* \[[@B21-cancers-11-00809],[@B23-cancers-11-00809]\].

To improve PPGL diagnostics and patient management we developed a comprehensive customized PPGL multi-gene panel for the analysis of PPGL tumor tissue, comprising 84 PPGL associated and candidate genes. We applied this to a cohort of 28 PPGL tumor samples and compared the results to our in-house PPGL cohort of patients who, over the course of several years, have undergone germline sequencing within a routine diagnostic setting.

2. Results {#sec2-cancers-11-00809}
==========

2.1. Routine Germline Testing in PPGL Patients Solves 30% of Cases {#sec2dot1-cancers-11-00809}
------------------------------------------------------------------

Between 2008 and 2017, 65 patients with PPGLs were referred to the Institute of Clinical Genetics in Dresden for genetic counselling and/or genetic testing. Thirty-one patients primarily presented with pheochromocytoma (PHEO) and 34 patients with paraganglioma (PGL), of which 25 were head and neck paragangliomas (HNP). The median age at diagnosis was 46.5 years (ranging from 13 to 77 years) and did not differ between those patients diagnosed with pheochromocytoma and those with paraganglioma. Eleven patients (17.2%) had developed PPGL until 30 years of age (y), while 27 patients had an age of onset over 50y (41.5%). Forty-two patients (64.6%) were female (18 PHEOs, 24 PGLs) and 23 patients (35.4%) were male (13 PHEOs, 10 PGLs).

Five of these patients (7.7%) had multiple PPGL tumors and 8 patients (12.3%) had additional tumors including adrenocortical adenoma/carcinoma, thyroid carcinoma, renal cell carcinoma, a testicular tumor, mamma carcinoma, Hodgkin's lymphoma and cervical carcinoma. Pedigree information was available in 53 of the patients and inconspicuous regarding relatives with tumors in 34 of them (64.2%). Three patients had relatives affected by paraganglioma, pheochromocytoma or gastrointestinal stromal tumor (GIST), indicating hereditary disease in these families, which was molecularly confirmed in all three cases. One family was known to carry a pathogenic *BRCA2* germline mutation causing hereditary breast and ovarian cancer. In addition, pedigree analysis of 3 further families was suspicious of hereditary breast and ovarian cancer, hereditary gastric cancer and hereditary colon cancer, respectively. Another 15 families were affected by additional cancers unrelated to PPGL and without fulfillment of criteria for a specific hereditary tumor predisposing syndrome. Clinical data are summarized in [Supplementary Table S1](#app1-cancers-11-00809){ref-type="app"}.

Germline testing of 11 PPGL susceptibility genes associated with known hereditary tumor predisposition syndromes associated with PPGLs (*SDHA, SDHB, SDHC, SDHD, SDHAF2, MAX, FH, NF1, RET, TMEM127* and *VHL*) was done in all of these patients, in the majority of cases using a combination of targeted multi-gene sequencing with the TruSight Cancer panel (Illumina, Inc., San Diego, CA, USA) in combination with customized array-based Comparative Genomic Hybridization (array-CGH) for copy number variation (CNV) calling \[[@B24-cancers-11-00809]\] and Sanger Sequencing of *SDHA* (for details see [Supplementary Table S1](#app1-cancers-11-00809){ref-type="app"})

In 19 of 65 cases (29.2%) we identified pathogenic or likely pathogenic germline mutations in a PPGL susceptibility gene, confirming a PPGL related hereditary tumor predisposition syndrome in these cases ([Table 1](#cancers-11-00809-t001){ref-type="table"}). The majority (14) of these patients had germline mutations in an *SDHx* gene, which is associated with an aberrant succinate to fumarate ratio (S:F ratio) in the tumor tissue. In eight cases with pathogenic germline *SDHx* variants, succinate and fumarate concentrations in the tumors were analyzed and aberrant S:F ratios were evident in six of these cases ([Table 1](#cancers-11-00809-t001){ref-type="table"}).

In one patient (ID3) with a pathogenic *SDHB* variant, we found an additional pathogenic germline variant in *CHEK2* (c.1100delC, p.(Thr367fs)) that is known to be associated with hereditary breast and ovarian cancer ([Table 1](#cancers-11-00809-t001){ref-type="table"}). In this case, an aberrant S:F ratio was not observed in the tumor although a pathogenic *SDHB* variant was identified, which might be explained by reported inconsistencies between *SDHx* mutations and aberrant S:F ratios in head and neck paragangliomas (HNPs) \[[@B21-cancers-11-00809]\].

2.2. Development of a Dedicated PPGL Custom Panel for Germline and Tumor Testing {#sec2dot2-cancers-11-00809}
--------------------------------------------------------------------------------

We designed a custom PPGL panel comprising a total of 84 genes, including 20 well-defined PPGL susceptibility genes (*EGLN1, EGLN2, MDH2, FH, SDHA, SDHB, SDHC, SDHD, SDHAF2, MAX, RET, TMEM127, VHL, EPAS1, NF1, H3F3A, IDH1, IDH2, ATRX,* and *HRAS*) that have been described to occur as germline, somatic or mosaic mutations in PPGL \[[@B2-cancers-11-00809],[@B4-cancers-11-00809]\]. Additionally, we included further common known tumor genes such as *TP53, PTEN, FGFR1,* and *BRAF* that have been described to be mutated in PPGL tumors and might be secondary mutations \[[@B18-cancers-11-00809],[@B19-cancers-11-00809],[@B22-cancers-11-00809]\]. Furthermore, we included candidate genes for PPGLs based on their gene function or gene family, e.g., genes encoding for metabolic enzymes or genes involved in epigenetic regulation (such as *TET1* and *TET2*) ([Figure 1](#cancers-11-00809-f001){ref-type="fig"}, [Supplementary Table S2](#app1-cancers-11-00809){ref-type="app"}). Some of these candidate genes have already been implicated to play a role in PPGL development, such as *KIF1B*, *GOT2,* and *IDH3B* \[[@B13-cancers-11-00809],[@B25-cancers-11-00809]\].

Importantly, we chose an enrichment-based protocol to enable even nucleotide coverages across target regions and to limit coverage fluctuations as best as possible. Even overall coverage enables robust CNV detection using next generation sequencing (NGS) data. Furthermore, the enrichment-based design can be adapted to be used, not only for high-quality DNA, but also for low-quality and fragmented DNA from paraffin-embedded (FFPE) tumor tissues. \[[@B26-cancers-11-00809]\]

2.3. Comprehensive Tumor Testing Improves Detection Rate of Underlying Mutations in PPGL-Patients {#sec2dot3-cancers-11-00809}
-------------------------------------------------------------------------------------------------

We first applied our novel customized PPGL panel to available tumor tissues of ten cases from our Dresden cohort that had undergone routine diagnostic germline testing. Four of the analyzed tumors were FFPE samples and six were freshly cryo-conserved tissue samples. Two of the cases (ID42 and ID43) had pathogenic germline variants in known PPGL susceptibility genes (*SDHB, SDHC*), whereas in eight cases, no pathogenic variants had been identified during routine germline testing ([Table 2](#cancers-11-00809-t002){ref-type="table"}). Sequencing of tumor tissue from the aforementioned ten patients led to the identification of pathogenic variants in known PPGL susceptibility genes in nine cases ([Table 2](#cancers-11-00809-t002){ref-type="table"}). In the two cases with pathogenic germline mutations, we could confirm both mutations in tumor tissue. In one of these cases (ID42), we observed increased allele frequency (85.4%) of the pathogenic *SDHB* variant, suggesting a loss of heterozygosity in this tumor ([Table 2](#cancers-11-00809-t002){ref-type="table"}). In the other case (ID43) with a pathogenic germline variant in *SDHC*, we found an additional pathogenic somatic variant in *ATRX* ([Table 2](#cancers-11-00809-t002){ref-type="table"}). In seven out of eight cases with inconspicuous germline analysis results, we identified pathogenic somatic variants in tumor tissue of the patients ([Table 2](#cancers-11-00809-t002){ref-type="table"}). Four of these cases (ID69, ID66, ID67 and ID24) had a somatic variant in a known PPGL susceptibility gene (*SDHB*, *SDHD*, and 2x *VHL*) that was not present in the matched blood sample, indicating a sporadic tumor development in these cases. The tumor ID69 with a pathogenic *SDHD* variant additionally harbored a somatic missense variant of unknown significance in *FH* (p.(Ala198Val)) with a low allele frequency (7.3%), indicating a potential secondary event. Pathogenic hot-spot variants in *HRAS* were identified in two cases (ID1 and ID68). In the seventh tumor (ID72), we found pathogenic variants in *TP53* and in *ATRX*. In all of these cases, the family history was inconspicuous and, to our knowledge, no other tumors were diagnosed in those patients. All cases with pathogenic variants in *SDHx* also had aberrant S:F ratios in tumor tissue, whereas cases with pathogenic variants in non-*SDHx* genes did not show elevated S:F ratios, demonstrating correlation between genomic and metabolomic analyses ([Table 2](#cancers-11-00809-t002){ref-type="table"}). Altogether, combined tumor and germline testing revealed causative mutations in 90% of the cases (9/10), confirming a sporadic tumor in seven cases.

Next, we applied our PPGL custom panel to 18 PPGL tumor samples (twelve freshly cryo-conserved and six FFPE samples) within the scope of a multi-center research project. This cohort consisted of twelve pheochromocytomas and six paragangliomas, two of which were head and neck paragangliomas.

In twelve of these 18 tumors, pathogenic variants in a known PPGL susceptibility gene were identified by PPGL custom panel sequencing ([Table 2](#cancers-11-00809-t002){ref-type="table"}). In four cases, germline status of pathogenic variants could be evaluated by targeted Sanger sequencing. In two cases (ID51, ID71), we found pathogenic variants in *SDHB*. The pathogenic nonsense mutation p.(Tyr61\*) in *SDHB* in case ID51 was confirmed to be a somatic variant \[[@B21-cancers-11-00809]\]. Furthermore, metabolome analysis of tumor tissue of case ID51 showed an elevated S:F ratio of 5178.2, which is concurrent with the pathogenic *SDHB* variant \[[@B21-cancers-11-00809]\]. The *SDHB* missense variant p.(Arg242Cys) in case ID71 showed a low allele frequency of 16.4%, indicating that this variant is likely somatic as well. However, in this case no elevated S:F ratio was detected in tumor tissue, which is likely attributable to known deviations between pathogenic *SDHx* variants and S:F ratio in head and neck paragangliomas \[[@B21-cancers-11-00809]\]. Pathogenic variants in *FH* were identified in tumor tissue of two cases (ID41 and ID82) and showed elevated fumarate to malate ratios, demonstrating correlation between genomic and metabolomic analyses \[[@B21-cancers-11-00809]\]. Both pathogenic *FH* variants were also identified in the germline of the patients by targeted analysis ([Table 2](#cancers-11-00809-t002){ref-type="table"}) \[[@B21-cancers-11-00809]\].

In four cases, we identified pathogenic variants in *NF1* (ID73, ID79, ID91 and ID92). One of these cases (ID92) had two different nonsense mutations in *NF1* (p.(Arg440\*) and p.(Arg2517\*)) at allele frequencies of 15.9% and 33.2%, respectively, which could also indicate somatic origin. Case ID73 had a *NF1* nonsense variant (p.(Gln514\*) at an allele frequency of 62.1%, case ID79 showed a pathogenic frameshift variant (p.(Ser2601fs)) in *NF1* with an allele frequency of 83.2% and ID91 had a pathogenic splice variant in *NF1* with an allele frequency of 39.9%. A pathogenic missense variant in *VHL* (p.(Arg167Gln) was identified in ID78 at an allele frequency of 49.6%. No blood samples were available for analysis in these five cases and thus, presence of the respective *NF1* or *VHL* variants in the germline of these patients could not be determined.

One tumor (ID75) harbored a somatic *IDH2* hot-spot mutation, in line with elevated D-2-hydroxyglutarate \[[@B21-cancers-11-00809]\]. Tumor ID60 presented with a known hot-spot mutation in *HRAS*. Although no germline sequencing data were available, it can be assumed that this hot-spot mutation was somatic based on the gene involved and the low allele frequency of the variant. In one tumor (ID80) we identified a nonsense mutation in ATRX (p.Glu481\*), however, only at a frequency of 5.4%. This might imply the alteration was a secondary event contributing to tumor maintenance, although no other pathogenic variants were found in this tumor using the PPGL custom panel.

Taken together, by sequencing analyses of altogether 28 tumor tissues using our PPGL panel, we identified 24 (likely) pathogenic variants in 21 tumor samples ([Table 2](#cancers-11-00809-t002){ref-type="table"}, [Figure 2](#cancers-11-00809-f002){ref-type="fig"}). The spectrum of genes involved in these 21 samples differs from the spectrum of mutated genes identified by routine germline testing in our clinical cohort of 65 patients ([Figure 2](#cancers-11-00809-f002){ref-type="fig"}b). For example, the majority of variants identified by germline testing involved *SDHx* genes, while *SDHx* mutations only account for about 30% of mutations found by tumor testing (14/19 germline variants in the clinical cohort compared to 7/24 variants in tumor tissues). In contrast, variants in *IDH2*, *TP53*, *ATRX*, *HRAS*, and *VHL* were exclusively found by tumor sequencing, and variants in *NF1* were more frequently found in tumor tissues (5/24 variants in 21 tumor cases) compared to germline testing (1/19 variants identified in our clinical cohort of 65 patients ([Figure 2](#cancers-11-00809-f002){ref-type="fig"}b).

In seven of 28 analyzed PPGL tumor samples, we found no underlying pathogenic variants in any of the 20 known PPGL susceptibility genes. In two of these seven cases, we identified potentially disease relevant variants. One tumor (ID61) had a missense variant in *ATRX* (p.(Asn53His)) at an allele frequency of 25%. This variant was not listed in databases such as gnomAD, ClinVar or dbSNP and has, to the best of our knowledge, not described in the literature \[[@B27-cancers-11-00809],[@B28-cancers-11-00809],[@B29-cancers-11-00809]\]. In the tumor of patient ID90 we identified a missense variant in the candidate gene *TET1* (p.(Val128Leu)) with an allele frequency of 26.1%. The variant was found two times in heterozygous state in the general population (gnomAD database) and is listed in dbSNP (rs142008363), but not in ClinVar. Based on current knowledge, we classified both variants as variants of unknown significance. Unfortunately, blood samples to confirm the somatic status were unavailable in both cases, although the allele frequencies indicate that these variants might be somatic.

2.4. Tumor Testing with Our PPGL Custom Panel Can Provide Additional Information about Secondary Somatic Changes {#sec2dot4-cancers-11-00809}
----------------------------------------------------------------------------------------------------------------

To gain additional information about further potentially pathogenic alterations, we performed NGS-based copy number variant (CNV) detection in all samples that were sequenced with the PPGL custom panel. A blood sample with a confirmed deletion of one *NF1* allele served as positive control for CNV detection and the *NF1* loss was reliably detected by the applied algorithms ([Figure 3](#cancers-11-00809-f003){ref-type="fig"}F).

Within our cohort of 28 PPGL tumors that were analyzed by custom panel sequencing, several pathogenic variants were found at high allele frequencies indicating a loss of heterozygosity ([Table 2](#cancers-11-00809-t002){ref-type="table"}). In two cases with pathogenic *SDHB* variants (ID42: frequency of 85.4% and ID51: frequency of 80%) loss of one *SDHB* allele was identified by CNV detection analysis ([Figure 3](#cancers-11-00809-f003){ref-type="fig"}a,b). Similarly, pathogenic variants at high allele frequencies in *FH* were found in ID41 (92.3%) and ID82 (82%). Neither of these cases showed an *FH* deletion, supporting a copy number neutral mechanism of loss of heterozygosity (LOH) ([Figure 3](#cancers-11-00809-f003){ref-type="fig"}C, [Supplementary Table S3](#app1-cancers-11-00809){ref-type="app"}).

Two tumors with inconspicuous sequencing results (ID76 and ID88) had high frequencies of CNVs compared to the other samples ([Supplementary Table S3, Supplementary Figure S1](#app1-cancers-11-00809){ref-type="app"}), including heterozygous loss of *TP53* in one tumor (ID76) and of *NF1* in the other tumor (ID88) ([Figure 3](#cancers-11-00809-f003){ref-type="fig"}D,E).

2.5. Identification of Variants in Candidate Genes {#sec2dot5-cancers-11-00809}
--------------------------------------------------

Sequencing of PPGL tumor tissue with the custom panel revealed rare variants in candidate genes in nine cases ([Table 3](#cancers-11-00809-t003){ref-type="table"}). All of these variants were missense variants and the significance of these variants is currently unknown. Two of these variants were found at low allele frequencies (ID61: *ATRX* p.(Asn53His) 25.2% and ID88: *TET1* p.(Val128Leu) 26.1%) in tumors that otherwise did not harbor a clear pathogenic or likely pathogenic mutation in a known PPGL susceptibility gene (see Section [Section 2.3](#sec2dot3-cancers-11-00809){ref-type="sec"}).

The other seven variants were identified in cases that also carried a pathogenic variant in a PPGL susceptibility gene and occurred at allele frequencies between 46% and 52.3% with the exception of *FH* p.(Ala198Val) with a frequency of 7.3% ([Table 3](#cancers-11-00809-t003){ref-type="table"}).

All seven variants were predicted to be pathogenic by several *in silico* prediction programs (ID41: *OGDHL* p.(Tyr447Cys), ID68: *GPT* p.(Glu210Cys), ID69: *FH* p.(Ala198Val), ID71: *PDHB* p.(Val174Met), ID78: *FGFR1* p.(Pro702Tyr), ID79: *HIST1H3B* p.(Pro44Gln) and ID82: *PCK2* p.(Arg155Cys), [Table 3](#cancers-11-00809-t003){ref-type="table"}). None of the selected variants was listed in ClinVar or occurred at a significant frequency in the general population (gnomAD) \[[@B27-cancers-11-00809],[@B28-cancers-11-00809]\]. Five of these variants were listed in dbSNP and two variants were identified as somatic variants in lung cancer (*FGFR1* p.(Pro702Tyr)) or in a colon carcinoma ((*GPT* p.(Glu210Cys), COSMIC database; ([Table 3](#cancers-11-00809-t003){ref-type="table"})) \[[@B29-cancers-11-00809],[@B30-cancers-11-00809]\].

Since these variants occurred together with clearly pathogenic variants and (with the exception of the *FH* variant) with an allele frequency of about 50%, they might be rare/private germline variants that are coincidental findings. Unfortunately, blood samples of these nine cases were not available to confirm or exclude the somatic status of these variants.

3. Discussion {#sec3-cancers-11-00809}
=============

PPGLs are rare but known to be the tumor type with the highest heritability, with 30--40% of patients carrying a predisposing germline mutation. A steadily growing number of 20 PPGL susceptibility genes has been identified to date, and several candidate genes are being investigated \[[@B2-cancers-11-00809],[@B5-cancers-11-00809]\]. Some of these genes have been found to be mutated both in the germline and somatically, while others only occur as somatic mutations \[[@B7-cancers-11-00809],[@B8-cancers-11-00809],[@B13-cancers-11-00809],[@B16-cancers-11-00809],[@B17-cancers-11-00809],[@B18-cancers-11-00809],[@B19-cancers-11-00809],[@B22-cancers-11-00809],[@B31-cancers-11-00809],[@B32-cancers-11-00809]\].

Analyses of both tumor and blood-derived DNA therefore aid in discrimination of sporadic from hereditary tumor forms \[[@B31-cancers-11-00809]\]. This information is crucial for stratifying the risk of synchronous or metachronous tumor development in PPGL patients both regarding additional PPGLs and regarding other tumor types that, respectively, are associated with some of the PPGL susceptibility genes such as gastrointestinal stromal tumors (GIST ) with *SDH*x mutations \[[@B33-cancers-11-00809]\].

In some patients, occurrence of PPGL is the first manifestation of a heritable syndrome such as Neurofibromatosis type 1 (NF1) that besides a tumor predisposition is usually accompanied by additional symptoms \[[@B34-cancers-11-00809],[@B35-cancers-11-00809]\]. Patients with hereditary conditions need to undergo genetic counselling and predictive testing can be offered to healthy family members. Healthy mutation carriers should then be included in tailored clinical surveillance programs for early detection of tumor development or other manifestations of disease. Depending on the gene affected, predictive testing can even be indicated in children and prenatal testing needs to be considered for severe conditions with highly variable phenotypic expression.

On the other hand, knowledge of somatic mutations can also be crucial for patient treatment and follow-up. Patients with pathogenic mutations in *SDHB* and *FH*, for example, have an elevated risk for malignant tumor development, regardless of whether the mutation was inherited or whether it occurred somatically \[[@B10-cancers-11-00809],[@B36-cancers-11-00809]\]. Diagnosis of malignancy of PPGLs can, with certainty, only be made based on detection of metastases and not histology \[[@B37-cancers-11-00809]\]. Therefore, patients with mutations associated with malignancy of tumors need to be followed up closely for metastatic disease. Moreover, knowledge of mutations, both somatic and germline, increasingly opens up the possibility for targeted therapeutic approaches \[[@B38-cancers-11-00809]\].

Taking these implications on clinical management into account, it is evident that patients can substantially benefit from combined genetic analysis of both blood and tumor-derived DNA. We found that in our cohort germline testing identified pathogenic mutations in PPGL core genes in 19 out of 65 patients (29.2%). This number complies with reported germline mutational rates of 30--40% in PPGL patients in the literature \[[@B1-cancers-11-00809],[@B2-cancers-11-00809],[@B3-cancers-11-00809],[@B4-cancers-11-00809],[@B31-cancers-11-00809]\]. Tumor analysis of 28 samples using the custom tailored PPGL panel revealed pathogenic mutations in 21 tumors (75%) of which 13 were available for germline testing (9 were from our routine clinical cohort who had received routine diagnostic testing, and 4 cases from our research cohort received targeted blood sequencing of variants after tumor testing, see [Table 2](#cancers-11-00809-t002){ref-type="table"}). About one third of these 13 mutations found in tumor tissue were also present in blood and therefore presumed to be germline, while two third of these pathogenic mutations had developed somatically. Aim et al. recently published similar results with a mutation detection rate of 74% for combined germline and somatic mutation testing with a custom panel comprising 17 genes. This study, however, identified half of the mutations to be of germline and half of somatic origin \[[@B31-cancers-11-00809]\]. This discrepancy could be explained by a high percentage of patients with seemingly sporadic tumors in our cohort. Average age of tumor onset for those 13 patients who received both germline and tumor analysis was 42 years and only one patient had proven malignant disease. None of these patients had a positive family history for PPGL-associated tumors.

While patients can benefit from combined tumor and germline analysis, this approach is generally hindered by both financial issues and organizational obstacles. We did observe such obstacles in our cohort for those patients of whom, due to anonymous inclusion in a multi-center trial, we could only analyze tumor tissue without having access to germline information. Interdisciplinary approaches, especially between pathologists and clinical geneticists, could aid in bringing together both germline and tumor sequencing results in order to provide attending physicians with comprehensive genetic data.

Commonly used commercial sequencing panels for cancers are usually designed to either be used in clinical genetics in search for predisposing germline variants (such as the TruSight Cancer panel used in our routine diagnostic approach) or for application in molecular pathology for identification of somatic (hot-spot) variants in tumor tissues with focus on FFPE samples. Our custom panel covers both, i.e., genes that are typically mutated in the germline in context of hereditary tumor diseases (such as *SDHx* or *FH*) and genes that are almost exclusively somatically mutated in PPGLs (such as *HRAS*, *ATRX*, *IDHx*, etc.). It is moreover suitable for testing of high-quality DNA from blood samples as well as low-quality DNA from FFPE tissue samples. Therefore, our PPGL panel can be applied to combined germline and tumor analysis, leading to a significant increase in detected mutations.

The mutational spectrum we observed was generally compliant with previously reported results \[[@B3-cancers-11-00809],[@B4-cancers-11-00809],[@B31-cancers-11-00809]\]. We did find a total of 3/28 (10.7%) somatically *ATRX* mutated tumors, which is presumed to be associated with aggressive disease \[[@B22-cancers-11-00809],[@B39-cancers-11-00809],[@B40-cancers-11-00809]\]. One of these patients had not developed any metastases at the time of investigation, one patient had recurrence of disease and for one patient, follow-up information was unavailable. The first patient additionally carried a pathogenic *SDHC* germline mutation, which is in line with the reported enrichment of *ATRX* mutations in *SDHx* mutated tumors \[[@B32-cancers-11-00809]\]. The second tumor showed a somatic pathogenic *TP53* mutation in addition to the *ATRX* truncating mutation. *TP53* mutations are rare in PPGLs compared to most other tumor types. However, it has been proposed they could have a synergistic effect on other driver mutations, and it seems plausible that both the *ATRX* and *TP53* mutations affected tumor development in this patient. Different from *ATRX* mutations, however, *TP53* mutations in PPGL have not been associated with more aggressive disease. \[[@B3-cancers-11-00809],[@B22-cancers-11-00809]\] The third patient in our cohort with an *ATRX* mutation was not identified to carry any other driver alterations and did only show a read frequency of 5.4% for the *ATRX* mutation. While sole *ATRX* mutations have been described to drive sporadic PPGL development, it could also be considered that in this patient a relevant second mutation might have escaped the analysis \[[@B32-cancers-11-00809],[@B39-cancers-11-00809]\].

Copy number variants (CNVs), for instance, are typically not detected by NGS-based variant calling \[[@B26-cancers-11-00809]\]. We therefore applied a CNV detection approach based on the sequencing data generated by our custom panel in order to complement single nucleotide variant (SNV) detection from both cryo-conserved tumor samples and paraffin embedded tissues. This approach detected both loss-of-heterozygosity and possibly disease-related mutations in several tumors. However, further improvements and validations would be needed in order to reliably apply this technique in a diagnostic setting. This might be of value, since array-CGH can be unreliable for highly degraded DNA from FFPE tumor samples. CNV-detection based on our NGS custom-panel data could therefore provide a feasible alternative for CNV detection in these cases.

Apart from possible CNV detection and combined tumor and germline analysis, our broad customized PPGL panel did show further advantages over limited diagnostic panels, such as possible detection of rare or unexpected genetic events. For example, we identified a somatic *IDH2* hot spot mutation (Arg172Gly) in a paraganglioma sample, as reported previously \[[@B21-cancers-11-00809]\]. In addition, several variants of unknown significance were identified in PPGL candidate genes, allowing for further investigation of these potentially relevant genes. Considering steady research advances in underlying genetic mechanisms of PPGLs, the panel can easily be extended to further target regions.

However, one limitation of common sequencing approaches, which also applies to our panel, is the identification of epigenetic events leading to PPGL development. In one patient in our cohort, who developed multiple tumors, no pathogenic mutation was identified by common sequencing approaches, since the underlying epigenetic event was hypermethylation of the *SDHC* promoter region, as was reported earlier \[[@B41-cancers-11-00809]\]. This example emphasizes that even with broad diagnostic sequencing panels, unsolved cases with suspicion of hereditary disease should be directed to research approaches. Metabolic data can substantially aid diagnostics by guiding the search for genetic alterations that escape routine genetic testing \[[@B21-cancers-11-00809],[@B23-cancers-11-00809],[@B41-cancers-11-00809]\].

Taking these results together, we propose an interdisciplinary approach for genetic analysis of PPGL that encompasses both tumor and germline sequencing and conclude that our custom designed PPGL panel provides a valid tool for the identification of SNVs from fresh frozen and paraffin-embedded tumor tissues. CNV detection can further be performed based on the data generated by our panel. Combined diagnostic and research approaches yield optimal results for comprehensive genetic characterization of PPGL patients.

4. Materials and Methods {#sec4-cancers-11-00809}
========================

4.1. Patient Cohort and Genetic Testing Strategy {#sec4dot1-cancers-11-00809}
------------------------------------------------

Sequencing of blood or tumor samples was conducted either within a diagnostic or a research setting after informed written consent was given by all patients at their respective centers of study inclusion. In a diagnostic setting, patients were initially seen by endocrinologists and referred to the Institute for Clinical Genetics for genetic counselling. Pedigrees were analyzed and germline analysis was initiated, covering PPGL core genes *SDHB, SDHC, SDHD, SDHAF2, MAX, FH, NF1, RET, TMEM127* and *VHL* either via Sanger-Sequencing and/or next generation sequencing using a commercially available gene panel (TruSight Cancer Panel, Illumina) \[[@B34-cancers-11-00809],[@B42-cancers-11-00809]\]. This was complemented by custom array-CGH analysis for detection of copy number variations and multiplex ligation-dependent probe amplification (MLPA) (*SDHA*). If a causative mutation was identified, genetic counselling and predictive testing in families as well as appropriate clinical management and/or study inclusion were initiated. If tumor samples were available, cases with no identified causative germline mutations were analyzed using our dedicated PPGL multi gene panel comprising 84 genes. Additionally, blood or tumor tissue samples were provided in anonymized fashion by several centers from Madrid, Nijmegen, Munich and Bethesda under the clinical protocol of the Prospective Monoamine-producing Tumor Study (coordinator Graeme Eisenhofer). A number of samples reported here have already been published in a study with a different research focus \[[@B21-cancers-11-00809]\]. Patients from the research cohort were either part of the Prospective Monoamine-producing Tumor Study (PMT study; <https://pmt-study.pressor.org/>) and/or Registry and Repository of biological samples of the European Network for the Study of Adrenal Tumours (ENS\@T) with ethic approval given at each participating institution (ethic codes: EK 189062010 (Dresden), 2011-334 (Nijmegen), 173-11 and 379-10 (Munich), 15/024 (Madrid), 2011/0020149 Ref. n. 59/11 (Florence)), or enrolled under the IRB Protocol 00-CH-0093 (NIH/Bethesda/USA). Patients from the diagnostic cohort signed informed consent for genetic testing in accordance with the German Genetic Diagnostics Act (GenDG).

4.2. Next Generation Sequencing Analysis {#sec4dot2-cancers-11-00809}
----------------------------------------

DNA was isolated either from blood or from tumor tissue samples provided fresh or formalin fixed paraffin embedded. NGS analysis was conducted on a NextSeq or MiSeq sequencing instrument (Illumina Inc., San Diego, CA, USA) using the TruSight Cancer sequencing panel (Illumina Inc., San Diego, CA, USA) in the case of diagnostic analysis or the custom designed PPGL Panel (Illumina Inc., San Diego, CA, USA [Supplementary Table S1](#app1-cancers-11-00809){ref-type="app"}) for research analysis.

Resulting fastq sequence files were aligned to the human reference genome hg19 (GRCh37) using the Biomedical Genomics Workbench 5.0 (Qiagen, Hilden, Germany). In the case of diagnostic analysis, variants were called with a fixed ploidy algorithm with a required minimum frequency of 10 %, 3 reads supporting the variant and a required minimum coverage of 10 reads. For research analysis of tumor tissue or blood, variants were called using a low frequency variant detection algorithm (no assumption of known sample ploidy) with a required minimum frequency of 5% and otherwise similar settings. Variant calling was restricted to target regions as defined by the bed files of the TruSight Cancer panel (Illumina Inc., San Diego, CA, USA) and the PPGL panel. Variant classification was performed in accordance with the standards and guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) \[[@B43-cancers-11-00809]\].

4.3. CNV Calling {#sec4dot3-cancers-11-00809}
----------------

NGS-based calling of copy number variations (CNVs) was performed with the R (<https://www.r-project.org/>, \[[@B44-cancers-11-00809]\]) package panelcn.MOPS \[[@B45-cancers-11-00809]\], a CNV detection tool for targeted panel NGS data, set to default parameters. DNA obtained from blood samples of ten healthy individuals was sequenced with the PPGL panel and served as normal controls for CNV detection. The absence of CNVs in known PPGL susceptibility genes (*SDHA*, *SDHB, SDHC, SDHD, SDHAF2, MAX, FH, NF1, RET, TMEM127* and *VHL)* in controls was confirmed by array-CGH. Additionally, a sample with a heterozygous deletion of *NF1* as previously identified by array-CGH was included as a positive control for CNV detection. For each sample, log2 values, statistical parameters and copy numbers (CNx; x = number of copies) were exported into a csv file ([Supplementary Table S3](#app1-cancers-11-00809){ref-type="app"}). Furthermore, for each sample, median log2ratios per gene were plotted for visualization ([Supplementary Figure S1](#app1-cancers-11-00809){ref-type="app"}).

4.4. Metabolite Analyses {#sec4dot4-cancers-11-00809}
------------------------

Succinate and fumarate were extracted with methanol from fresh or FFPE tissue as previously reported \[[@B23-cancers-11-00809]\] and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). Methodological details have previously been reported \[[@B21-cancers-11-00809]\].

5. Conclusions {#sec5-cancers-11-00809}
==============

Comprehensive testing of tumor samples can improve diagnostics in PPGL patients. We propose parallel testing of blood and tumor tissue (fresh frozen or FFPE), accompanied by metabolite profiling, immunohistochemistry and additional analyses such as methylation detection to allow for better data interpretation. In the future, current NGS panel designs have to be updated to facilitate integration of newly discovered susceptibility genes or could even be replaced by exome sequencing. Patients can substantially benefit from integrating diagnostic and research approaches for molecular characterization of PPGLs.
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![Schematic overview of the custom pheochromocytoma and paraganglioma (PPGL) panel. Known PPGL susceptibility genes and expected occurrences (germline, somatic) are depicted in the upper panel. Candidate gene categories are depicted in the lower panel. (m): mosaic, *TERT^P^: TERT promoter region.*](cancers-11-00809-g001){#cancers-11-00809-f001}

![Summarized outcome of sequencing analysis of pheochromocytoma and paraganglioma (PPGL) susceptibility genes by diagnostic sequencing of blood samples in a clinical cohort of 65 patients and next generation sequencing analysis of 28 tumor tissues using our PPGL panel. Ten patients received both, diagnostic blood sequencing and tumor analysis, and are included in both cohorts. (**a**) We found (likely) pathogenic mutations in 21 of 28 tumors (75%), including three samples with more than one mutation (see [Table 2](#cancers-11-00809-t002){ref-type="table"}); four of those patients had confirmed germline variants (dark grey); in four patients, germline status of the variant is unknown (grey); 13 cases had either confirmed somatic mutations or presumably somatic mutations based on the genes involved and/or the allele frequencies of the variants (light grey). Routine clinical blood testing in the clinical cohort of 65 patients identified 19 cases with germline mutations (29.2%). (**b**) Different spectrum of genes found to be mutated when performing blood testing (19 (likely) pathogenic variants identified in 19 of 65 blood samples) or tumor testing (24 (likely) pathogenic variants identified in 21 of 28 tumor samples). Numbers indicate how many variants were identified per gene.](cancers-11-00809-g002){#cancers-11-00809-f002}

![Results of next generation sequencing based copy number variant detection. (**a**) *SDHB* of case ID42, (**b**) *SDHB* of case ID51, (**c**) *FH* of case ID41, (**d**) *TP53* of case ID76, (**e**) *NF1* of case ID88, (**f**) *NF1* of a control sample with an experimentally proven *NF1* deletion; dots represent single targets of the respective genes, green lines highlight a log2 value of 0, dotted red lines mark log2 values of +0.5 and −0.5.](cancers-11-00809-g003){#cancers-11-00809-f003}

cancers-11-00809-t001_Table 1

###### 

Overview of (likely) pathogenic germline variants (ACMG classes 4/5) identified during routine testing.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  ID     Diagnosis   Solitary/Multiple   AD/Gender   Family History       Gene      Nucleotide Change   Amino Acid Change   S:F Ratio in Tumor Tissue
  ------ ----------- ------------------- ----------- -------------------- --------- ------------------- ------------------- ---------------------------
  ID45   PHEO        unknown             30/f        unknown              FH        c.434C \> G         p.(Ser145\*)        0.14

  ID11   PHEO        solitary            59/m        unknown              FH        c.1431_1433dupAAA   p.(Lys477dup)       n.a.

  ID32   PHEO        multiple            39/f        1 melanoma (AO 35)   NF1       c.6084+1G \> A      p.?                 n.a.

  ID52   PHEO        multiple            47/f        inconspicuous        RET       c.1901G \> T        p.(Cys634Phe)       5.5

  ID56   HNP         unknown             23/m        unknown              SDHA      c.553_554insA       p.(Ala186fs)        n.a.

  ID62   PGL         solitary            37/f        inconspicuous        SDHA      c.1338delA          p.(His447fs)        n.a.

  ID35   PGL/HNP     multiple            52/f        1 melanoma (AO 48)   SDHAF2    c.232G \> A         p.(Gly78Arg)        217.3

  ID3    HNP         solitary            17/m        inconspicuous        SDHB\     c.649C \> T\        p.(Arg217Cys)\      24.1
                                                                          CHEK2     c.1100delC          p.(Thr367fs)        

  ID42   PGL         solitary            51/m        cancers (AO \> 50)   SDHB      c.287-3 C \> G      p.?                 1472.7

  ID4    PGL/HNP     multiple            23/f        cancers (AO \> 50)   SDHB      deletion exon 3                         n.a.

  ID55   HNP         unknown             26/f        unknown              SDHB      c.806delT           p.(Met269fs)        n.a.

  ID86   PGL         solitary            33/m        unknown              SDHB      c.649C \> T         p.(Arg217Cys)       n.a.

  ID19   HNP         solitary            36/f        cancers (AO \> 50)   SDHB      c.725G \> A         p.(Arg242His)       5908.3

  ID63   PGL         solitary            48/m        cancers (AO \> 50)   SDHC      c.397C \> T         p.(Arg133\*)        45.4

  ID48   HNP         solitary            69/f        inconspicuous        SDHC      c.43C \> T          p.(Arg15\*)         n.a.

  ID43   PHEO        solitary            50/m        cancers (AO \> 50)   SDHC      c.379C \> T         p.(His127Tyr)       795.5

  ID34   HNP         solitary            34/m        2 PGLs               SDHD      c.53-2A \> G        p.?                 278.3

  ID38   HNP         solitary            47/f        1 PGL                SDHD      c.49C \> T          p.(Arg17\*)         920.6

  ID59   HNP         unknown             68/f        unknown              TMEM127   c.465_466insACTTG   p.(Ala156fs)        n.a.
  -----------------------------------------------------------------------------------------------------------------------------------------------------

AD: age at diagnosis, AO: age of onset, PHEO: pheochromocytoma, PGL: paraganglioma, HNP: head & neck paraganglioma, S:F ratio: succinate to fumarate ratio.

cancers-11-00809-t002_Table 2

###### 

(Likely) pathogenic variants (ACMG classes 4/ 5) identified in tumor samples.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
         Diagnosis   AD/Gender   Gene      Nucleotide Change   Amino Acid Change      VAF (Tumor)   LOH   Somatic Status    Germline Testing \*   S:F Ratio
  ------ ----------- ----------- --------- ------------------- ---------------------- ------------- ----- ----------------- --------------------- -----------
  ID80   PHEO        65/m        *ATRX*    c.1441G \> T        p.(Glu481\*)           5.4%          no    likely somatic    no                    46.2

  ID82   PHEO        31/f        *FH*      c.700A \> G         p.(Thr234Ala)          82.0%         yes   germline          yes (targeted)        0.4

  ID41   PHEO        37/m        *FH*      c.816_836del        p.(Ala273_Val279del)   92.3%         yes   germline          yes (targeted)        0.3

  ID68   PHEO        66/f        *HRAS*    c.182A \> G         p.(Gln61Arg)           56.8%         no    somatic           yes                   66.3

  ID1    PHEO        52/f        *HRAS*    c.182A \> G         p.(Gln61Arg)           72.0%               somatic           yes                   17.7

  ID60   PHEO        27/f        *HRAS*    c.37G \> C          p.Gly13Arg             26.0%         no    somatic           no                    12.8

  ID75   HNP         53/f        *IDH2*    c.514A \> G         p.Arg172Gly            24.5%         no    somatic           yes (targeted)        5.3

  ID73   PHEO        56/f        *NF1*     c.1540C \> T        p.(Gln514\*)           62.1%               unknown           no                    16.6

  ID79   PHEO        58/f        *NF1*     c.7798_7799insA     p.(Ser2601fs)          83.2%         yes   unknown           no                    47.5

  ID91   PHEO        50/m        *NF1*     c.205-1G \> T       p.?                    39.9%         no    unknown           no                    unknown

  ID92   PHEO        73/f        *NF1*\    c.1318C \> T\       p.(Arg440\*)\          15.9%\        no\   likely somatic\   no                    unknown\
                                 *NF1*     c.7549C \> T        p.(Arg2517\*)          33.2%         no    unknown                                 unknown

  ID51   PGL         56/m        *SDHB*    c.183T \> G         p.(Tyr61\*)            80.0%         yes   somatic           yes (targeted)        5178.2

  ID42   PGL         51/m        *SDHB*    c.287-3C \> G       p.?                    85.4%         yes   germline          yes                   1472.7

  ID71   HNP         49/m        *SDHB*    c.724C \> T         p.(Arg242Cys)          16.4%         no    likely somatic    no                    24.7

  ID43   PHEO        50/m        *SDHC*\   c.379C \> T\        p.(His127Tyr)\         46.6%\        no    germline\         yes                   795.5
                                 *ATRX*    c.2817del           p.(Ala940fs)           65.8%               likely somatic                          

  ID69   HNP         27/f        *SDHD*    c.3G \> T           p.(Met1Ile)            18.2%         no    somatic           yes                   405.9

  ID24   PGL         21/m        *SDHD*    c.337_340del        p.(Asp113fs)           41.5%               somatic           yes                   1756.8

  ID72   PHEO        66/f        *TP53*\   c.817C \> T\        p.(Arg273Cys)\         74.1%\              somatic\          yes                   5.7
                                 *ATRX*    c.4744_4745insA     p.(Thr1582fs)          61.2%               unknown                                 

  ID67   PGL         31/f        *VHL*     c.193T \> G         p.(Ser65Ala)           8.5%          no    somatic           yes                   24.1

  ID66   PHEO        13/m        *VHL*     c.193T \> G         p.(Ser65Ala)           17.4%         no    somatic           yes                   21.4

  ID78   PHEO        47/f        *VHL*     c.500G \> A         p.(Arg167Gln)          49.6%         no    unknown           no                    17.4
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

\* Information about germline status was either available from routine germline testing in the patients included from our clinical cohort (indicated with "Germline testing yes") or due to targeted Sanger sequencing of blood samples ("yes (targeted)"). ACMG: American College of Medical Genetics, AD: age at diagnosis, LOH: loss of heterozygosity PHEO: pheochromocytoma, PGL: paraganglioma, HNP: head and neck paraganglioma, S:F ratio: succinate to fumarate ratio, VAF: variant allele frequency.

cancers-11-00809-t003_Table 3

###### 

Overview of variants of unknown significance in candidate genes.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ID     Gene         Nucleotide Change   Amino Acid Change   VAF (Tumor)   gnomAD\   SIFT        PolyPhen            COSMIC                dbSNP          Pathogenic Variants
                                                                            het/hom                                                                        
  ------ ------------ ------------------- ------------------- ------------- --------- ----------- ------------------- --------------------- -------------- ---------------------
  ID61   *ATRX*       c.157A \> C         p.(Asn53His)        25.2%         0/0       tolerated   probably damaging   \-                    \-             no

  ID78   *FGFR1*      c.2104C \> A        p.(Pro702Thr)       49.6%         0/0       damaging    probably damaging   1 × lung              \-             yes (*VHL*)

  ID69   *FH*         c.593C \> T         p.(Ala198Val)       7.3%          0/0       damaging    probably damaging   \-                    \-             yes (*SDHD*)

  ID68   *GPT*        c.628G \> A         p.(Glu210Lys)       46.0%         0/0       damaging    probably damaging   1 × large intestine   rs1366336459   yes (*HRAS*)

  ID79   *HIST1H3B*   c.131C \> A         p.(Pro44Gln)        52.3%         0/0       damaging    n.a.                \-                    \-             yes (*NF1*)

  ID41   *OGDHL*      c.1340A \> G        p.(Tyr447Cys)       51.1%         32/0      damaging    probably damaging   \-                    rs148307090    yes (*FH*)

  ID82   *PCK2*       c.463C \> T         p.(Arg155Cys)       50.9%         30/0      damaging    probably damaging   \-                    rs141787425    yes (*FH*)

  ID71   *PDHB*       c.520G \> A         p.(Val174Met)       47.7%         1/0       damaging    probably damaging   \-                    rs760966357    yes (*SDHB*)

  ID88   *TET1*       c.382G \> C         p.(Val128Leu)       26.1%         2/0       tolerated   benign              \-                    rs142008363    no
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VAF: variant allele frequency, het: heterozygous, hom: homozygous, SIFT: Sorting Intolerant From Tolerant (*in silico* variant effect prediction), COSMIC: the Catalogue Of Somatic Mutations In Cancer.

[^1]: These authors contributed equally.
